Aclaris Launched Phase 2b Trial Of Modzatinib For Lichen Planus; Stock Down
Aclaris Therapeutics (ACRS) began a Phase 2b trial for modzatinib, an oral treatment for moderate-to-severe lichen planus. The trial will enroll 100 patients, with results expected in late 2027. The FDA granted Fast Track designation to modzatinib. ACRS stock is down 8.08% in pre-market trading.
How this was made
The 30-second read
Why it matters
The Phase 2b launch and Fast Track status represent the first public disclosure of this program, prompting an 8% pre‑market decline.
Market read
First report of a mid‑stage trial for a niche dermatology indication; likely short‑term price pressure.
What to watch
Potential partnership or licensing deals for modzatinib could offset trial risk.
Background
Aclaris Therapeutics (NASDAQ: ACRS) is a clinical‑stage biotech focused on inflammatory diseases.
Ticker impact
Aclaris Therapeutics announced the initiation of a Phase 2b trial of modzatinib for moderate-to-severe lichen planus.
likely further downside as investors price in trial risk and await data.
New trial start and Fast Track designation introduce uncertainty; early‑stage data often moves the share price.
Market effects
adds a pipeline candidate to the dermatology/immune‑modulation biotech space.
US biotech sector may see modest pressure.
Limited; relevance confined to investors tracking early‑stage biotech trials.
Counterpoint
If the trial shows early safety signals, the stock could rebound despite the initial sell‑off.
Key entities
- companyAclaris Therapeutics
Biotech developer of modzatinib.


